^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Viadur (leuprorelin implant)
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Bayer, J&J
Drug class:
GnRH stimulant
Related drugs:
1m
NRG-GU002: Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (clinicaltrials.gov)
P2/3, N=612, Completed, NRG Oncology | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Oct 2025 | Trial primary completion date: May 2026 --> Oct 2025
Trial completion • Trial completion date • Trial primary completion date
|
docetaxel • Eligard (leuprolide acetate) • bicalutamide • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Viadur (leuprorelin implant)
2ms
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers (clinicaltrials.gov)
P2, N=21, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Enrollment closed
|
Eligard (leuprolide acetate) • Nubeqa (darolutamide) • Viadur (leuprorelin implant)
4ms
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (clinicaltrials.gov)
P3, N=27, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Dec 2025 --> Jun 2026
Trial primary completion date
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Eligard (leuprolide acetate) • Nubeqa (darolutamide) • triptorelin • goserelin acetate • Viadur (leuprorelin implant)
9ms
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
P2, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2025 --> Mar 2026
Trial completion date
|
Eligard (leuprolide acetate) • bicalutamide • goserelin acetate • Viadur (leuprorelin implant)
9ms
SHARP: Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
P2, N=25, Active, not recruiting, City of Hope Medical Center | Trial completion date: Apr 2025 --> Feb 2026 | Trial primary completion date: Apr 2025 --> Feb 2026
Trial completion date • Trial primary completion date
|
Eligard (leuprolide acetate) • goserelin acetate • Firmagon (degarelix) • Xofigo (radium Ra-223 dichloride) • Viadur (leuprorelin implant)
11ms
NCI-2018-01856: Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (clinicaltrials.gov)
P2, N=310, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2025 --> Feb 2027 | Trial primary completion date: Feb 2025 --> Feb 2027
Trial completion date • Trial primary completion date
|
abiraterone acetate • Eligard (leuprolide acetate) • bicalutamide • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Viadur (leuprorelin implant) • Yonsa (abiraterone acetate)
12ms
SATURN: Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer (clinicaltrials.gov)
P2, N=28, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2026
Trial completion date • Trial primary completion date
|
abiraterone acetate • Eligard (leuprolide acetate) • apalutamide • Viadur (leuprorelin implant)
12ms
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (clinicaltrials.gov)
P3, N=27, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Jun 2025 --> Dec 2025
Trial primary completion date
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Eligard (leuprolide acetate) • Nubeqa (darolutamide) • triptorelin • goserelin acetate • Viadur (leuprorelin implant)
1year
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (clinicaltrials.gov)
P3; Trial primary completion date: May 2028 --> Jun 2025
Trial primary completion date • Surgery
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Eligard (leuprolide acetate) • Nubeqa (darolutamide) • triptorelin • goserelin acetate • Viadur (leuprorelin implant)
over1year
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
P1, N=14, Recruiting, Roswell Park Cancer Institute | Trial completion date: Apr 2027 --> Oct 2027 | Trial primary completion date: Apr 2026 --> Oct 2026
Trial completion date • Trial primary completion date • Metastases
|
Eligard (leuprolide acetate) • Viadur (leuprorelin implant)
over1year
NRG-GU002: Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (clinicaltrials.gov)
P2/3, N=612, Active, not recruiting, NRG Oncology | N=175 --> 612 | Trial completion date: May 2031 --> May 2026
Enrollment change • Trial completion date • Surgery
|
docetaxel • Eligard (leuprolide acetate) • bicalutamide • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Viadur (leuprorelin implant)
over1year
NRG-GY033: Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors (clinicaltrials.gov)
P2, N=37, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
Trial suspension • Combination therapy
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
exemestane • Eligard (leuprolide acetate) • Nubeqa (darolutamide) • Viadur (leuprorelin implant)
Share via
